Recently, FDA approved the use of Rufinamide as a new anti-epileptic drug, the first and only triazole derivative for this medical treatment. This is a relatively new drug, it is understood that chemistry (synthesis) and biology (pharmacology-pharmacovigilance) of this compound is currently new. In order to delve into the understanding of the chemistry of said compound, for this work, the obtaining of Rufinamide analogues was carried out, applying as a synthetic strategy cycloaddition (3 + 2) azide-enolate. Reactions were under mild conditions and subsequent hydrolysis. With good yields.

Síntesis de nuevos análogos de la Rufinamida vía cicloadiciones (3+2) azida–enolato

LatinXChem

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.